Posted by Michael Wonder on 27 Dec 2023
Coherus announces FDA approval of Udenyca Onbody, a novel and proprietary state of the art delivery system for pegfilgrastim-cbqv
26 December 2023 - Innovative design enables five minute pegfilgrastim delivery time.
Coherus BioSciences today announced that the US FDA approved Udenyca Onbody, the company's on body injector presentation of Udenyca (pegfilgrastim-cbqv), a pegfilgrastim biosimilar administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.
